Therapeutic Antibodies for Veterinary Medicine
adivo developed a technology platform for the selection of species-specific therapeutic antibodies for veterinary medicine. These antibodies had predefined characteristics that enabled the generation of lead candidates with optimal functionality for dogs and other animals. After the ongoing collaboration in canine antibody drug discovery since 2021, which was expanded to include adivo’s novel feline antibody library in 2022, the exit to Zoetis Inc. (NYSE:ZTS), the global leader in animal health, took place in 2023.